Gastroenteropancreatic neuroendocrine tumors

被引:0
|
作者
Rayes, Nada [1 ]
Denecke, Timm [2 ]
机构
[1] Univ Klinikum Leipzig, Klin & Poliklin Viszeral Transplantat Thorax & Ge, Liebigstr 20, D-04103 Leipzig, Germany
[2] Univ Klinikum Leipzig, Klin & Poliklin Diagnost & Intervent Radio, Leipzig, Germany
来源
ONKOLOGE | 2021年 / 27卷 / 05期
关键词
Neuroendocrine tumors; registries; treatment algorithms; Chromogranin  A; Receptors; somatostatin; Peptide receptor radionuclide therapy; ENETS CONSENSUS GUIDELINES; MANAGEMENT; CLASSIFICATION; STANDARDS; UPDATE; CARE;
D O I
10.1007/s00761-021-00911-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neuroendocrine tumors (NET), or more generally neuroendocrine neoplasms (NEN), represent a very heterogeneous group of rare tumors with varying location which are only defined by their endocrine biology and secretion of synaptophysin and chromogranin A. They originate from mesoderm-derived stem cells. In the last few years, the incidence and prevalence of NEN have been steadily increasing. Classification is based on the affected organ, the proliferation rate and presence or absence of hormone production with typical symptoms. Diagnosis and treatment of these tumors is therefore very specific and requires an interdisciplinary approach. Treatment options include endoscopic or surgical resection, drug therapy for control of symptoms and proliferation, locoregional therapy and radionuclide therapy. Guidelines with algorithms for diagnostic workup and treatment are constantly updated.
引用
收藏
页码:511 / 520
页数:10
相关论文
共 50 条
  • [31] Hereditary neuroendocrine tumors of the gastroenteropancreatic system
    Martin Anlauf
    Nele Garbrecht
    Juliane Bauersfeld
    Anja Schmitt
    Tobias Henopp
    Paul Komminoth
    Philipp U. Heitz
    Aurel Perren
    Günter Klöppel
    Virchows Archiv, 2007, 451 : 29 - 38
  • [32] Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Tumors
    Phan, Alexandria T.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (12) : 3 - 5
  • [33] Prognostic Factors in Gastroenteropancreatic Neuroendocrine Tumors
    Srirajaskanthan, R.
    Toumpanakis, C.
    Desai, K.
    Warner, B.
    Subash, S.
    Caplin, M. E.
    NEUROENDOCRINOLOGY, 2009, 90 (01) : 135 - 135
  • [34] Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors
    Venkata K. Pokuri
    Mei Ka Fong
    Renuka Iyer
    Current Oncology Reports, 2016, 18
  • [35] Surgical Management of Gastroenteropancreatic Neuroendocrine Tumors
    Kenney, Lisa M.
    Hughes, Marybeth
    CANCERS, 2025, 17 (03)
  • [36] Neuroendocrine Gastroenteropancreatic Tumors: Where Are We?
    Ulla Rocha, Jose L.
    Salgado, Angel
    Sardina Ferreiro, Raquel
    Fernandez Catalina, Pablo
    Gallardo, Elena
    SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES, 2017, 27 (01): : 36 - 41
  • [37] Gastroenteropancreatic Neuroendocrine Tumors: Update on Therapeutics
    Ganetsky, Alex
    Bhatt, Valkal
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (06) : 851 - 862
  • [38] Duration of Surveillance for Gastroenteropancreatic Neuroendocrine Tumors
    Chi, Weiwei
    Warner, Richard R.
    Chen, William C.
    Wisnivesky, Juan
    Kim, Michelle K.
    GASTROENTEROLOGY, 2015, 148 (04) : S127 - S127
  • [39] Gastroenteropancreatic Neuroendocrine Tumors: A Case Series
    Braimoh, Grace A.
    Asamoah, Vivian
    Le, Dona
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S1738 - S1738
  • [40] The role of endoscopy in gastroenteropancreatic neuroendocrine tumors
    Magno, L.
    Sivero, L.
    Napolitano, V.
    Ruggiero, S.
    Fontanarosa, G.
    Massa, S.
    GIORNALE DI CHIRURGIA, 2010, 31 (6-7): : 341 - 343